Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...
Charles Schwab Investment Management Inc. Has $20.96 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
Charles Schwab Investment Management Inc. grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) ...
ETF Daily News4d
Denali Therapeutics Inc. (NASDAQ:DNLI) Position Increased by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 33.8% in the fourth quarter, HoldingsChannel reports.
Zacks.com on MSN5d
Why You Shouldn't Bet Against Denali (DNLI) Stock
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Nasdaq5d
Why You Shouldn't Bet Against Denali (DNLI) Stock
One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health ...
American Association of Individual Investors1d
3 Undervalued Pharmaceuticals Stocks for Monday, March 24
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, March 24, 2025. Let’s take ...